Table 2

Clinical and biological characteristics of the 481 early RA patients who had a follow-up assessment of 12 months

Early RA patients n = 481Baseline (T0)Follow-up (T12)
Gender: female, n (%)358 (74.4)
Age, years54.4±12.0
Disease duration, months6.4±3.3
VERA, n (%)105 (21.8)
DMARD only, n (%)329 (68.4)
Anti-TNF, n (%)152 (31.6)
Tender joint count (28 joints)9.0±5.32.8±3.3
Swollen joint count (28 joints)6.4±4.61.8±2.4
PhGA (0–100)49.8±20.124.8±25.4
PGA (0–100)60.6±19.827.0±23.3
VAS pain (0–100)59.3±22.424.4±21.9
GH (0–100)55.9±19.758.7±28.9
HAQ (0–3)1.15±0.60.5±0.5
ESR, mm/1st h38.9±21.923.2±15.5
CRP, mg/l23.0±26.08.6±12.6
Erosive patients, n (%)168 (34.9)264 (54.9)
  • CRP, C-reactive protein; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GH, general health; HAQ, health assessment questionnaire; TNF, tumour necrosis factor; PGA, patient global assessment; PhGA, physician global assessment; RA, rheumatoid arthritis; VAS, visual analogue scale; VERA, very early rheumatoid arthritis.